NAMPT
Nicotinamide phosphoribosyl transferase; PBEF; Visfatin; pre-B cell-enhancing factor; Pre-B cell colony enhancing factor
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme which catalyzes the conversion of nicotinamide (NAM) and phosphoribosyl-pyrophosphates to nicotinamide mononucleotide (NMN) in the mammalian nicotinamide adenine dinucleotide (NAD+) synthetic salvage pathway. NAMPT exists in two forms, intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT).
iNAMPT levels are high in brown adipose tissue (BAT), liver and kidney, intermediate in white adipose tissue (WAT), lung, spleen, testes and skeletal muscle, and undetectable in brain and pancreas. eNAMPT, thought to be produced through post-translational modification of iNAMPT, is released into plasma predominantly from adipose tissue, where it catalyses the synthesis of NMN. Although intracellular NAMPT is a key enzyme in controlling NAD metabolism, eNAMPT has been reported to function as a cytokine, with many roles in physiology and pathology. Circulating eNAMPT has been associated with several metabolic and inflammatory disorders, including cancer.
All Product Categories
-
NAMPT Related Products (90)
Related Products (90)
-
Antibodies (2)
-
Nampt activator-5
0 ImagesCat. No.: HY-162269CAS No.: 3041005-21-1Nampt activator-5 is a NAMPT activator with a KD value of 6.19 μM. Nampt activator-5 activates the rate-limiting enzyme in NAD+ biosynthesis and promotes NAD+ production. Nampt activator-5 delays the senescence process of senescent hepatocytes, extends the lifespan of *Caenorhabditis elegans*, and alleviates age-related dysfunction and abnormal biomarkers in naturally aged mice. Nampt activator-5 can be used in aging research.
-
Nampt-IN-10
0 ImagesCat. No.: HY-W1117786CAS No.: 2241015-68-7Nampt-IN-10 (Compound 4) is an efficient inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). Nampt-IN-10 exhibits nanomolar-level inhibitory activity against cell lines such as MDA-MB453, NCI-N87, and NCI-H526. Nampt-IN-10 can be used as an ADC payload, and the ADC constructed with it as the core demonstrates significant anti-tumor activity.
-
PDEδ/NAMPT IN-1
0 ImagesCat. No.: HY-172919CAS No.: 2976498-55-0PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (KD=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC50=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD+), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer.
-
PD-L1/Nampt-IN-1
0 ImagesCat. No.: HY-175294CAS No.: 3054043-85-2PD-L1/Nampt-IN-1 is an orally active inhibitor that simultaneously target PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50s value of 63 nM and 582 nM. PD-L1/Nampt-IN-1 demonstrates cross-species affinity with comparable KD values for hPD-L1 (52.6 nM) and mPD-L1 (49.1 nM), respectively. PD-L1/Nampt-IN-1 effectively inhibits tumor growth by activating the tumor immune microenvironment. PD-L1/Nampt-IN-1 can be used for the study of melanoma.
-
L2-FK866
0 ImagesCat. No.: HY-181911L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research.
-
Nampt-IN-9
0 ImagesCat. No.: HY-147838CAS No.: 2180973-35-5Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research.
-
Nampt-IN-20
0 ImagesCat. No.: HY-184467CAS No.: 1362150-16-0Nampt-IN-20 is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor with a IC50 of 9.0 nM. Nampt-IN-20 binds to the active site of Nampt, occupies the NAM-binding region and disrupts NAD biosynthesis. Nampt-IN-20 exerts antiproliferative effects in A2780 ovarian cancer cells. Nampt-IN-20 can be used for the research of ovarian cancer.
-
CAIX/XII/NAMPT-IN-1
0 ImagesCat. No.: HY-181350CAIX/XII/NAMPT-IN-1 is a triple inhibitor of carbonic anhydrase IX/XII and nicotinamide phosphoribosyltransferase (NAMPT) with a hCA IX Ki of 78.1 nM, hCA XII Ki of 64.4 nM, and hNAMPT IC50 of 168 nM. CAIX/XII/NAMPT-IN-1 induces apoptosis, ROS accumulation, suppresses ERK/AKT signaling, inhibits DNA synthesis, and causes mitochondrial dysfunction. CAIX/XII/NAMPT-IN-1 exerts antiproliferative effects against multiple cancer cells under normoxic and hypoxic conditions. CAIX/XII/NAMPT-IN-1 can be used for the research of cancer, such as renal carcinoma, glioblastoma and colorectal cancer.
-
Gibberellin A34
0 ImagesCat. No.: HY-W587952CAS No.: 32630-92-5Gibberellin A34 is a Hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1) inhibitor that can be isolated from immature seeds of Calonyction aculeatum. Gibberellin A34 can be used for studies on plant growth and development regulation.
-
JGB-1-155
0 ImagesCat. No.: HY-163280CAS No.: 3011930-28-9JGB-1-155 is a nicotinamide phosphoribosyltransferase (NAMPT) activator and also a reactive oxygen species (ROS) inhibitor. JGB-1-155 binds to NAMPT, thereby enhancing its catalytic activity and increasing intracellular NAD+ levels. JGB-1-155 alleviates the elevation of ROS levels induced by various types of damage. JGB-1-155 can be used in research related to neurodegenerative diseases.
-
Nampt-IN-13
0 ImagesCat. No.: HY-164759CAS No.: 2592504-89-5Nampt-IN-13 is a NAMPT inhibitor that serves as a payload for the synthesis of ADCs. Nampt-IN-13 is applicable to cancer-related research.
-
PROTAC NAMPT Degrader-1
0 ImagesCat. No.: HY-163440CAS No.: 3102963-15-2
-
HDAC/NAMPT-IN-1
0 ImagesCat. No.: HY-162124CAS No.: 2898381-63-8
-
PROTAC NAMPT Degrader-28
0 ImagesCat. No.: HY-181880PROTAC NAMPT Degrader-28 is a NAMPT PROTAC degrader with DC50 values of 45 nM and 55 nM in MCF7 and 4T1cl5 cells, respectively. PROTAC NAMPT Degrader-28 retains nicotinamide phosphoribosyltransferase inhibitory activity and does not induce degradation of this enzyme. PROTAC NAMPT Degrader-28 can be used in breast cancer-related research.
-
Mutant IDH1/NAMPT-IN-1
0 ImagesCat. No.: HY-158319CAS No.: 3040122-14-0Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutant IDH1) (IC50=14.93 nM) and nicotinamide phosphoribosyltransferase (NAMPT) (IC50=12.56 nM). Mutant IDH1/NAMPT-IN-1 can induce apoptosis. Mutant IDH1/NAMPT-IN-1 crosses the blood-brain barrier effectively.
-
Nampt-IN-16
0 ImagesCat. No.: HY-176237CAS No.: 3077970-44-3Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD+ and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer.
-
GR2-128
0 ImagesCat. No.: HY-184396GR2-128 is a dual inhibitor targeting MLK3 and NAMPT with IC50 values of 84 nM and 14 nM, respectively. GR2-128 inhibits downstream JNK/c‑Jun signaling and reduces NAD+ levels. GR2-128 exhibits antiproliferative and pro-apoptotic activities in triple-negative breast cancer cells without significant toxicity to normal cells. GR2-128 suppresses tumor growth, reduces macrophage and neutrophil infiltration, and increases tumor T-cell markers in a syngeneic mouse model, and can be used for triple-negative breast cancer research.
